Nautilus Biotechnology (NAUT) EPS (Basic) (2020 - 2026)
Nautilus Biotechnology (NAUT) posted EPS (Basic) of -$0.4 for Q2 2026, up 5.14% sequentially from -$0.42 in Q2 2025, and up 5.14% YoY from -$0.38 in Q2 2025.
Nautilus Biotechnology (NAUT) EPS (Basic) (2020 - 2026) Analysis & Trends
Nautilus Biotechnology has reported EPS (Basic) for 4 years, with the latest figure at -$0.4 in Q2 2026.
- Quarterly EPS (Basic) rose 5.14% year-over-year to -$0.4 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$0.4 (up 5.14% YoY) and the FY2020 annual result came in at -$1.42, changed N/A from the prior year.
- EPS (Basic) climbed to -$0.4 in Q2 2026 per NAUT's latest filing, from -$0.42 in the prior quarter.
- Over five years, EPS (Basic) peaked at -$0.4 in Q2 2026 and troughed at -$0.42 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 7.59 |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -1.96 |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.23 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.06 |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 0.18 |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -0.72 |
| 10 | Nautilus Biotechnology | 114.43 Mn | 114.43 Mn | 175,000.00 | -0.11 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.40 |
| Jun 30, 2025 | -0.42 |
| Mar 31, 2021 | -0.14 |
| Dec 31, 2020 | -0.05 |
| Sep 30, 2020 | -0.04 |